ERBB2 and breast cancer: About 10 to 20% of breast cancer are triple‐negative for lacking significant expression of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2).3 Triple‐negative breast cancer (TNBC) is more aggressive and has poorer prognosis than other breast malignancies.